<DOC>
	<DOCNO>NCT00850577</DOCNO>
	<brief_summary>The purpose study determine efficacy CT-322 comparative bevacizumab , combination carboplatin paclitaxel treatment chemonaive subject recurrent advance non-squamous NSCLC</brief_summary>
	<brief_title>Ph II Novel Anti-angiogenic Agent Combination With Chemotherapy Treatment Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>For additional information , please contact BMS oncology clinical trial information service 8552160126 email MyCancerStudyConnect @ emergingmed.com . Please visit www.BMSStudyConnect.com information clinical trial participation . ECOG Performance Status ( PS ) &lt; =1 Histologically cytologically confirm , stage IIIB ( malignant pleural effusion ) , stage IV recurrent NSCLC Measurable disease RECIST guideline Evidence predominantly squamouscell histology Known CNS metastases Any prior antineoplastic systemic regimen NSCLC Excessive risk bleeding ( include use therapeutic anticoagulation ) history thrombotic embolic cerebrovascular accident Gross hemoptysis ( â‰¥1/2 tsp red blood ) Uncontrolled hypertension Clinically significant cardiovascular disease History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 6 month Serious nonhealing wound , active peptic ulcer , nonhealing bone fracture , bleed skin metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>